Status: Recruiting
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.
Participants needed: 150
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Jun 11, 2026Locations: 59
Eligibility criteria
Participants with clinical tumour stage T2-T4aN0/1M0 or T1N1M0 with transitional... [+4]
Evidence of lymph node (N2-N3) or metastatic (M1) disease [+5]